tetano
Editor, Senior Moderator
Diagn Microbiol Infect Dis
. 2022 Jan 22;115640.
doi: 10.1016/j.diagmicrobio.2022.115640. Online ahead of print.
Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir
Yuki Hanai[SUP] 1 [/SUP], Sadako Yoshizawa[SUP] 2 [/SUP], Kazuhiro Matsuo[SUP] 3 [/SUP], Shusuke Uekusa[SUP] 3 [/SUP], Taito Miyazaki[SUP] 4 [/SUP], Koji Nishimura[SUP] 5 [/SUP], Takumi Mabuchi[SUP] 5 [/SUP], Hayato Ohashi[SUP] 5 [/SUP], Yoshikazu Ishii[SUP] 6 [/SUP], Kazuhiro Tateda[SUP] 6 [/SUP], Takashi Yoshio[SUP] 3 [/SUP], Kenji Nishizawa[SUP] 5 [/SUP]
Affiliations
Abstract
The objective of this retrospective study was to identify the clinical risk factor associated with uric acid elevation in coronavirus disease (COVID-19) patients treated with favipiravir. Uric acid elevation was defined as an unexplained increase of ≥1.5 times in the patient's uric acid level from baseline. Twenty-nine COVID-19 patients were included in the study. Uric acid elevation developed during favipiravir therapy in 12 (41.4%) patients and the median onset time was 4.5 days after starting favipiravir. In multiple logistic regression analysis, the favipiravir dosage (adjusted OR = 1.69 [1.02-2.81], P = 0.044) and younger patient age (adjusted OR = 0.91 [0.83-0.99], P = 0.040) were significant clinical risk factors for uric acid elevation. No significant between-group difference was noted in the uric acid elevation and non-elevation groups in the clinical recovery after favipiravir therapy. The uric acid levels of patients administered with favipiravir should be monitored closely.
Keywords: Antiviral therapy; COVID-19; Favipiravir; SARS-CoV-2; Uric acid elevation.
. 2022 Jan 22;115640.
doi: 10.1016/j.diagmicrobio.2022.115640. Online ahead of print.
Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir
Yuki Hanai[SUP] 1 [/SUP], Sadako Yoshizawa[SUP] 2 [/SUP], Kazuhiro Matsuo[SUP] 3 [/SUP], Shusuke Uekusa[SUP] 3 [/SUP], Taito Miyazaki[SUP] 4 [/SUP], Koji Nishimura[SUP] 5 [/SUP], Takumi Mabuchi[SUP] 5 [/SUP], Hayato Ohashi[SUP] 5 [/SUP], Yoshikazu Ishii[SUP] 6 [/SUP], Kazuhiro Tateda[SUP] 6 [/SUP], Takashi Yoshio[SUP] 3 [/SUP], Kenji Nishizawa[SUP] 5 [/SUP]
Affiliations
- PMID: 35193798
- DOI: 10.1016/j.diagmicrobio.2022.115640
Abstract
The objective of this retrospective study was to identify the clinical risk factor associated with uric acid elevation in coronavirus disease (COVID-19) patients treated with favipiravir. Uric acid elevation was defined as an unexplained increase of ≥1.5 times in the patient's uric acid level from baseline. Twenty-nine COVID-19 patients were included in the study. Uric acid elevation developed during favipiravir therapy in 12 (41.4%) patients and the median onset time was 4.5 days after starting favipiravir. In multiple logistic regression analysis, the favipiravir dosage (adjusted OR = 1.69 [1.02-2.81], P = 0.044) and younger patient age (adjusted OR = 0.91 [0.83-0.99], P = 0.040) were significant clinical risk factors for uric acid elevation. No significant between-group difference was noted in the uric acid elevation and non-elevation groups in the clinical recovery after favipiravir therapy. The uric acid levels of patients administered with favipiravir should be monitored closely.
Keywords: Antiviral therapy; COVID-19; Favipiravir; SARS-CoV-2; Uric acid elevation.